Innoviva (INVA) Tax Provisions (2014 - 2026)
Innoviva's (INVA) quarterly Tax Provisions came in at $48.0 million in Q1 2026, up 499.6% YoY from $8.0 million in Q1 2025, and up 93.42% on a QoQ basis from $24.8 million in Q3 2025.
Analysis
Innoviva (INVA) Tax Provisions (2014 - 2026) Analysis & Trends
Innoviva (INVA) has 11 years of Tax Provisions data on file, last reported at $48.0 million in Q1 2026.
- Quarterly Tax Provisions rose 499.6% year-over-year to $48.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $89.7 million (up 315.06% YoY) and the FY2024 annual result came in at $26.6 million, up 1757.15% from the prior year.
- Tax Provisions improved to $48.0 million in Q1 2026, from $24.8 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $63.1 million in Q3 2022 to a low of -$4.6 million in Q2 2024.
- A 5-year average of $15.2 million and a median of $8.6 million in 2024 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2023 — Tax Provisions surged 600.0% — and 2024, when it plunged 202.09%.
- Tracing INVA's Tax Provisions over 5 years: stood at $63.1 million in 2022, then slumped by 76.68% to $14.7 million in 2023, then tumbled by 34.72% to $9.6 million in 2024, then surged by 158.33% to $24.8 million in 2025, then surged by 93.42% to $48.0 million in 2026.
- The last three Tax Provisions figures came in at $48.0 million (Q1 2026), $24.8 million (Q3 2025), and $8.9 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | -24.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -24.60 Mn |
| Mar 31, 2026 | 48.00 Mn |
| Sep 30, 2025 | 24.81 Mn |
| Jun 30, 2025 | 8.91 Mn |
| Mar 31, 2025 | 8.00 Mn |
| Sep 30, 2024 | 9.63 Mn |
| Jun 30, 2024 | -4.60 Mn |
| Mar 31, 2024 | 8.60 Mn |
| Sep 30, 2023 | 14.71 Mn |
| Jun 30, 2023 | 4.53 Mn |
| Mar 31, 2023 | 6.30 Mn |
| Sep 30, 2022 | 63.10 Mn |
| Jun 30, 2022 | -900,000.00 |
| Mar 31, 2022 | 6.90 Mn |
| Sep 30, 2021 | 65.60 Mn |
| Jun 30, 2021 | 25.33 Mn |
| Mar 31, 2021 | 19.74 Mn |
| Dec 31, 2020 | 29.69 Mn |
| Sep 30, 2020 | 8.90 Mn |
| Jun 30, 2020 | 19.90 Mn |